Germany agrees deal with CureVac, GSK for mRNA vaccines until 2029 | Reuters
Germany has signed a contract with CureVac and its British partner GlaxoSmithKline for supply of domestically produced mRNA vaccines until 2029 in case of public health emergencies, the German biotech firm said on Monday.